ready to fly?, page-3

From here, we can only go up. Previous valuations were taking the price toward $0.50.
They were based on an expected start of sales in Europe (of a device), but now actually we have a double effect as current clinical trial will cover both a Phase II USA FDA IND submission and, and I repeat and, a EMA European submission.
At the end of this successful clinical process we will have a completed USA FDA Phase II trial (with a Phase III to be executed together with a partner) and a ready to go material to be approved by EMA.
Let's remind that the European Agency did not challenge the validity of the product, but just the lack of patients data.

Technically, the first target of $0.14 is very conservative and just a jump platform toward the $0.50 and possibly a $1 future valuation once we will have completed this very important set of clinical trials.

Let's remind that the 53 patient trial performed in Europe had been very successful.
The result were well above average, if not really outstanding!

We are positive and we are loading based on future expectations.